Products 2018-11-05T10:36:07+00:00

Products

Bellus Medical products carve out a unique space in the aesthetics industry.

Our non-invasive innovations – SkinPen®, the first-ever FDA-cleared microneedling device; the post-microneedling protocol Skinfuse®; the light-activated cream Allumera®; and the platelet-rich plasma systems ProGenTM and RegenLab®  – act as “gateway” products that draw new consumers to leading physician-directed practices around the world.

SkinPen by Bellus Medical

SKINPEN®

The First FDA-Cleared Microneedling
Device in the World1

SkinFuse by Bellus Medical

SKINFUSE®

Custom Post-Microneedling Protocol

ProGen PRP by Bellus Medical

PROGENTM

Flexible Platelet-Rich Plasma System2

RegenLab One-Step Closed Platelet-Rich Plasma System

REGENLAB®

One-Step Closed Platelet-Rich Plasma System3

Allumera light-activated photodynamic cosmetic cream

ALLUMERA®

The Light-Activated Cream for Skin Revitalization4

Become A Provider
References
[1] SkinPen® U.S. intended use: The SkinPen Precision System is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years and older. Rx only. SkinPen® international intended use: SkinPen Precision is a microneedling device that utilizes collagen induction therapy to treat melasma, acne and surgical scars. See intended use, important safety information, and clinical trial details (data on file) at skinpen.com. [2] ProGen™ intended use: The ProGen PC Kit is indicated for the rapid preparation of autologous Platelet Rich Plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP is mixed with autograft/or allograft bone prior to the application to a bony defect for improving handling characteristics of the graft. [3]RegenLab® intended use: All models or A-CP-K Family kits are designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling. [4] Revitall study of safety and efficacy of Allumera® and skin illumination in 101 subjects (data on file). Results based on a survey conducted by patients after three procedures spaced four weeks apart.